Brivanib (BMS-540215) | VEGFR2 Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	649735-46-6
Formula :	C₁₉H₁₉FN₄O₃
M.W :	370.38
SMILES Code :	C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C
Synonyms :	BMS-540215
MDL No. :	MFCD13194684
InChI Key :	WCWUXEGQKLTGDX-LLVKDONJSA-N
Pubchem ID :	11234052

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H317
Precautionary Statements:	P280

HepG2-SR cells	2.5, 5 μM	48 hrs/72 hrs	Brivanib, as a positive control, reduced the viability of HepG2-SR cells and induced apoptosis.	PMC9120623
HepG2	60 μM	72 h	To evaluate the effect of Notch3 silencing on Brivanib response, results showed that Notch3 silencing enhanced the apoptotic effect of Brivanib on HepG2 cells.	PMC6461893
Huh7	60 μM	72 h	To evaluate the effect of Notch3 silencing on Brivanib response, results showed that Notch3 silencing enhanced the apoptotic effect of Brivanib on Huh7 cells.	PMC6461893
Hep3B	60 μM	72 h	To evaluate the effect of Notch3 silencing on Brivanib response, results showed that Notch3 silencing did not significantly enhance the apoptotic effect of Brivanib on Hep3B cells.	PMC6461893

Mice	MCF-7 E2 tumor model	Oral	0.05 mg/g and 0.1 mg/g	Daily for 6 weeks	To evaluate the effect of Brivanib Alaninate on the growth of MCF-7 E2 tumors. Results showed that the high dose (0.1 mg/g) significantly inhibited tumor growth, while the low dose (0.05 mg/g) had no significant effect.	PMC2927957
mice	RIP1-Tag2 transgenic mice	oral	75 mg/kg	once daily for 5.5 weeks	To evaluate the therapeutic efficacy of Brivanib in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors (PNET). Results showed that Brivanib treatment significantly extended the lifespan of the mice and maintained tumor stasis during the 5.5 weeks of therapy.	PMC3156934
BALB/c- nu/nu mice	HepG2-SR hepatoma model	Oral administration	100 mg/kg	Once daily for 15 consecutive days	Brivanib, as a positive control, significantly inhibited HepG2-SR tumor growth.	PMC9120623
Mice	Liver fibrosis models induced by bile duct ligation (BDL), chronic carbon tetrachloride (CCl4), and chronic thioacetamide (TAA)	Oral	25 mg/kg, 50 mg/kg, 100 mg/kg	Administered for 5 consecutive days with 2 days off on weekends, lasting for 4 weeks	To evaluate the effect of brivanib on liver fibrosis, results showed that brivanib significantly reduced liver fibrosis and decreased the expression of collagen Iα1 and α-smooth muscle actin in the liver.	PMC3977817
Rats	DENA-induced HCC model	Oral gavage	60 mg/kg	Once daily for 15 days	To evaluate the effect of Brivanib combined with Notch3 silencing on the HCC model, results showed that Notch3 silencing significantly enhanced the inhibitory effect of Brivanib on tumor growth.	PMC6461893

{[proInfo.proName]}

CAS No.: 649735-46-6

{[proInfo.proName]}

CAS No.: 649735-46-6

Alternative Products

Product Details of Brivanib

Safety of Brivanib

Related Pathways of Brivanib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00594984	Metastatic Colorectal Cancer (... More >>MCRC) Less <<	Phase 1 Phase 2	Completed	-	United States, California ... More >> Usc/Norris Comprehensive Cancer Center Hospital Los Angeles, California, United States, 90033 Usc/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Kentucky James Graham Brown Cancer Center Louisville, Kentucky, United States, 40202 United States, Missouri Washington University Saint Louis, Missouri, United States, 63110 Argentina Local Institution Buenos Aires, Argentina, C1426ANZ Denmark Local Institution Odense C, Denmark, 5000 Italy Local Institution Meldola Fc, Italy, 47014 Local Institution Milano, Italy, 20141 Korea, Republic of Local Institution Seoul, Korea, Republic of, 135-710 Spain Local Institution Madrid, Spain, 28050 Sweden Local Institution Stockholm, Sweden, 17176 Local Institution Uppsala, Sweden, 75185 Less <<
NCT00300027	Gastrointestinal Neoplasms	Phase 1	Terminated	-	United States, Arkansas ... More >> Local Institution Little Rock, Arkansas, United States United States, California Local Institution Los Angeles, California, United States United States, District of Columbia Local Institution Washington, District of Columbia, United States United States, Iowa Local Institution Iowa City, Iowa, United States United States, North Carolina Local Institution Durham, North Carolina, United States United States, Texas Local Institution Temple, Texas, United States Less <<
NCT01046864	Gastro-Intestinal Cancer	Phase 1	Completed	-	United States, California ... More >> Usc/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Texas Texas Oncology Dallas, Texas, United States, 75246 Scott & White Memorial Hospital And Clinic Temple, Texas, United States, 76508 Canada, Alberta Local Institution Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Local Institution Ottawa, Ontario, Canada, K1H 8L6 France Local Institution Villejuif Cedex, France, 94800 Less <<
NCT00207103	Tumors Neopla... More >>sm Metastasis Less <<	Phase 1	Completed	-	United States, California ... More >> Premiere Oncology Santa Monica, California, United States, 90404 United States, Indiana Indiana University Med Center Indianapolis, Indiana, United States, 46202 United States, Wisconsin University Of Wisconsin Comprehensive Center Madison, Wisconsin, United States, 53792 Canada, Alberta Local Institution Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Local Institution Ottawa, Ontario, Canada, K1H 1C4 Italy Local Institution Milano, Italy, 20141 United Kingdom Local Institution Middlesex, Greater London, United Kingdom, HA6 2RN Local Institution Manchester, Greater Manchester, United Kingdom, M20 4BX Less <<
NCT00858871	Hepato Cellular Carcinoma (HCC... More >>) Less <<	Phase 3	Completed	-	-
NCT00798252	Advanced Cancer	Phase 1	Completed	-	United States, California ... More >> Usc/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Wayne State University Detroit, Michigan, United States, 48201 Canada, Alberta Local Institution Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Local Institution Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT01253668	Renal Cell Carcinoma	Phase 2	Completed	-	United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00390936	Solid Tumors	PHASE1	COMPLETED	2025-03-10	Local Institution, Sunto-Gun, ... More >>Shizuoka, 411-8777, Japan Less <<
NCT00640471	Colorectal Cancer	Phase 3	Completed	-	-
NCT00908752	Hepatocellular Carcinoma	Phase 3	Completed	-	-
NCT00207051	Colorectal Cancer	Phase 1	Completed	-	United States, California ... More >> Usc/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, District of Columbia Georgetn Univ Lombardi Can Ctr Washington, District of Columbia, United States, 20007 United States, Florida University Of Miami Miller School Of Medicine Miami, Florida, United States, 33010 H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Canada, Ontario Local Institution Hamilton, Ontario, Canada, L8V 2C5 Local Institution Toronto, Ontario, Canada, M5G 2M9 Netherlands Local Institution Amsterdam, Netherlands, 1081 HV Less <<
NCT00435669	Tumors	Phase 1	Completed	-	United States, Ohio ... More >> Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Less <<
NCT00888173	-		Completed	-	-
NCT01267253	Cervical Adenocarcinoma ... More >> Cervical Adenosquamous Carcinoma Cervical Squamous Cell Carcinoma, Not Otherwise Specified Persistent Disease Recurrent Cervical Carcinoma Less <<	Phase 2	Active, not recruiting	-	-
NCT01267253	-		Active, not recruiting	-	-
NCT00355238	Hepatocellular Carcinoma (HCC)	Phase 2	Completed	-	-
NCT00437424	Carcinoma, Hepatocellular	PHASE1	COMPLETED	2025-06-10	University Of Alabama At Birmi... More >>ngham, Birmingham, Alabama, 35294, United States\|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States\|Case Western Reserve University, Clleveland, Ohio, 44106, United States\|South Texas Accelerated Research Therapeutics, Llc, San Antonio, Texas, 78229, United States\|Local Institution, Sevilla, 41013, Spain Less <<
NCT00633789	Advanced Non-small Cell Lung C... More >>ancer Transitional Cell Carcinoma Soft Tissue Sarcoma Gastric/Esophageal Adenocarcinoma Pancreatic Cancer Including Ampulla of Vater Less <<	Phase 2	Completed	-	-
NCT01367275	Colorectal Cancer ... More >> Colorectal Adenocarcinoma Less <<	Phase 2	Terminated(Sponsor closed stud... More >>y) Less <<	-	United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01108705	Carcinoma, Hepatocellular	Phase 3	Terminated	-	-
NCT00888173	Endometrial Adenocarcinoma ... More >> Endometrial Clear Cell Adenocarcinoma Endometrial Mixed Adenocarcinoma Endometrial Mucinous Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Squamous Cell Carcinoma Endometrial Transitional Cell Carcinoma Endometrial Undifferentiated Carcinoma Recurrent Uterine Corpus Carcinoma Less <<	Phase 2	Completed	-	-
NCT03516071	Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	May 10, 2019	China, Anhui ... More >> Anhui Provincial Hospital Recruiting Hefei, Anhui, China Contact: Yueyin Pan China, Guangdong Nanfang Hospital Recruiting Guangzhou, Guangdong, China Contact: Jinlin Hou Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China Contact: Li Xu China, Heilongjiang Harbin Medical University Cancer Hospital Recruiting Harbin, Heilongjiang, China Contact: Yuxian Bai China, Henan Henan Cancer Hospital Recruiting Zhengzhou, Henan, China Contact: Xinfang Hou China, Hunan Hunan Cancer Hospital Recruiting Changsha, Hunan, China Contact: Shanzhi Gu China, Jiangsu China PLA 81st hospital Recruiting Nanjing, Jiangsu, China Contact: Shukui Qin China, Jilin The first Hospital of Jilin University Recruiting Changchun, Jilin, China Contact: Wei Li China, Liaoning Army General Hospital of Shenyang military region Recruiting Shenyang, Liaoning, China Contact: Zhendong Zheng China, Shanghai Fudan University Shanghai Cancer Center Recruiting Shanghai, Shanghai, China Contact: Zhiqiang Meng Zhongshan Hospital Recruiting Shanghai, Shanghai, China Contact: Zhenggang Ren China, Shanxi Tangdu Hospital Recruiting Xi'an, Shanxi, China Contact: Helong Zhang China, Sichuan West China Hospital West China School of Medicine Sichuan University Recruiting Chengdu, Sichuan, China Contact: Hong Zhu China, Tianjin Tianjin Medical University Cancer Institute & Hospital Recruiting Tianjin, Tianjin, China Contact: Tianqiang Song China, Zhejiang Zhejiang Cancer Hospital Recruiting Hangzhou, Zhejiang, China Contact: Jieer Ying Less <<
NCT00825955	Liver Cancer	Phase 3	Terminated(Efficacy endpoint m... More >>et, however, overall experimental dosing regimen is not considered optimal to support further clinical development in this patient population) Less <<	-	-
NCT01540461	Hepatocellular Carcinoma	PHASE1	COMPLETED	2025-11-13	Local Institution, Beijing, Be... More >>ijing, 100071, China\|Local Institution, Ha Erbin, Heilongjiang, 150040, China\|Local Institution, Nanjing, Jiangsu, 210002, China Less <<
NCT00437437	Tumors	PHASE1	COMPLETED	2025-02-13	Dana-Farber Harvard Cancer Car... More >>e, Boston, Massachusetts, 02115, United States\|Wayne State University, Detroit, Michigan, 48201-2194, United States\|Duke University Medical Center-Dept Of Medicine, Durham, North Carolina, 27710, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.70mL 0.54mL 0.27mL	13.50mL 2.70mL 1.35mL	27.00mL 5.40mL 2.70mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed